Protein amidation is the process through which a carboxyl group is converted into an amide group.

The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.

The emergence of oligonucleotide drugs makes it possible to actively design drug sequences to target and silence disease genes.

At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.

FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.

ROCK2 inhibitors are drugs targeting the ROCK2 enzyme, crucial in various cellular processes.

Maze Therapeutics has commenced the administration phase of its Phase 1 clinical evaluation of MZE829 to test subjects in good health.

Site-directed mutagenesis is a molecular biology technique that is used to make specific and intentional changes to the DNA sequence of a gene and any protein that it may encode.

1ST Biotherapeutics, Inc. breaks new ground as it initiates the first human trial stage I/II by administering FB849, to individuals with progressive solid cancers

TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations.

C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Oligonucleotide drugs are a class of medications that are composed of short, synthetic pieces of DNA or RNA known as oligonucleotides.